RO.CH

267.8

+0.07%↑

NOVN.CH

95.11

+0.44%↑

RO.CH

267.8

+0.07%↑

NOVN.CH

95.11

+0.44%↑

RO.CH

267.8

+0.07%↑

NOVN.CH

95.11

+0.44%↑

RO.CH

267.8

+0.07%↑

NOVN.CH

95.11

+0.44%↑

RO.CH

267.8

+0.07%↑

NOVN.CH

95.11

+0.44%↑

Search

Lonza Group AG

Cerrado

SectorSalud

556.8 -1.59

Resumen

Variación precio

24h

Actual

Mínimo

555.8

Máximo

568.2

Métricas clave

By Trading Economics

Ingresos

307M

Ventas

3.5B

P/B

Media del Sector

54.451

40.048

BPA

4.31

Rentabilidad por dividendo

0.71

Margen de beneficio

8.729

Empleados

19,299

EBITDA

764M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+18.16% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.71%

2.45%

Próximas Ganancias

23 oct 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-2.5B

40B

Apertura anterior

558.39

Cierre anterior

556.8

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

175 / 374 Clasificación en Healthcare

Lonza Group AG Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

23 jul 2025, 08:30 UTC

Ganancias
Principales Movimientos del Mercado

Lonza Shares Rise After Outlook Lift for Core Business

9 may 2025, 05:18 UTC

Ganancias

Lonza Doesn't Expect Tariff Hit, Backs Outlook for CDMO Business

18 feb 2025, 12:22 UTC

Adquisiciones, fusiones, absorciones

Lonza Picks BofA, Centerview Partners for Capsules Unit Sale, Bloomberg Law Says, Citing Sources

23 jul 2025, 08:00 UTC

Charlas de Mercado
Ganancias

Lonza Nudges Up Full-Year Guidance for Core Business After Good Results -- Market Talk

23 jul 2025, 04:44 UTC

Ganancias

Lonza 1H Sales Grew 19% at Constant Currency

23 jul 2025, 04:43 UTC

Ganancias

Lonza 1H Core Ebitda Margin 29.6%

23 jul 2025, 04:43 UTC

Ganancias

Lonza: Margins Will Be Only Minimally Affected

23 jul 2025, 04:42 UTC

Ganancias

Lonza Expects FX Headwind of -2.5% to -3.5% on 2025 Sales and Core Ebitda

23 jul 2025, 04:42 UTC

Ganancias

Lonza: This Is Mainly From Weakening of U.S. Dollar

23 jul 2025, 04:38 UTC

Ganancias

Lonza 1H Net Pft CHF426M

23 jul 2025, 04:37 UTC

Ganancias

Lonza Backs 2025 View for CHI Business

23 jul 2025, 04:36 UTC

Ganancias

Lonza Had Seen CDMO Business Core Ebitda Margin Approaching 30% in 2025

23 jul 2025, 04:36 UTC

Ganancias

Lonza Sees CDMO Business Core Ebitda Margin of 30%-31% in 2025

23 jul 2025, 04:35 UTC

Ganancias

Lonza Had Expected 2025 CDMO Business Sales Growth at Constant Currency of About 20%

23 jul 2025, 04:35 UTC

Ganancias

Lonza Expects 2025 CDMO Business Sales Growth at Constant Currency of 20%-21%

23 jul 2025, 04:33 UTC

Ganancias

Lonza Upgrades 2025 Full-Year CDMO Sales and Margin Outlook

23 jul 2025, 04:32 UTC

Ganancias

Lonza 1H EBITDA CHF1.01B

23 jul 2025, 04:32 UTC

Ganancias

Lonza 1H Core Ebitda CHF1.06B

23 jul 2025, 04:32 UTC

Ganancias

Analysts Saw Lonza 1H Sales at CHF3.51B

23 jul 2025, 04:32 UTC

Ganancias

Analysts Saw Lonza 1H Core Ebitda at CHF1.00B

23 jul 2025, 04:31 UTC

Ganancias

Lonza 1H Sales CHF3.58B

23 jul 2025, 04:31 UTC

Ganancias

Lonza Backs 2025 View

25 jun 2025, 05:27 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Lonza Group Looks Well-placed to Benefit From U.S. Pharma Trade Policy -- Market Talk

28 may 2025, 05:38 UTC

Charlas de Mercado

Lonza Looks Like Tariff Winner -- Market Talk

9 may 2025, 14:45 UTC

Charlas de Mercado

Big Pharma's U.S. Expansion Will Take Years to Materialize, Lonza CFO Says -- Market Talk

9 may 2025, 14:42 UTC

Charlas de Mercado

Big Pharma U.S. Investment Plans Might Not Bring Extra Spending, Lonza CFO Says -- Market Talk

8 abr 2025, 07:34 UTC

Charlas de Mercado

Lonza Well Protected From Tariffs -- Market Talk

29 ene 2025, 08:11 UTC

Charlas de Mercado
Ganancias

Lonza's Outlook Looks Positive -- Market Talk

29 ene 2025, 07:22 UTC

Charlas de Mercado
Ganancias

Lonza Had a Mixed Year Across Divisions -- Market Talk

29 ene 2025, 07:11 UTC

Charlas de Mercado
Ganancias

Lonza's Results Don't Contain Any Surprises -- Market Talk

Comparación entre iguales

Cambio de precio

Lonza Group AG Esperado

Precio Objetivo

By TipRanks

18.16% repunte

Estimación a 12 meses

Media 675.89 CHF  18.16%

Máximo 753 CHF

Mínimo 630 CHF

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Lonza Group AG Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

8

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

175 / 374 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.